EpiCast Report: Pancreatic Cancer - Epidemiology Forecast to 2022
London (PRWEB) November 06, 2013 -- Summary
Pancreatic cancer is one of the most fatal cancers around the world, with the highest incidence and mortality rates found in developed countries (Michaud, 2004). Pancreatic cancer originates from transformed cells from tissues within the exocrine component of the pancreas. The most common type is adenocarcinoma associated with the exocrine gland (ACS, 2013). The pancreas is found deep within the body, leading to the inability to detect pancreatic cancer early-on. Most cases of pancreatic cancer go undetected from the lack of obvious symptoms, causing the cancer to spread to other organs.
The risk of developing pancreatic cancer is associated with increasing age, as more than 75% of pancreatic cancer patients are over the age of 60 years (SEER Cancer Statistics Review, 2012). Tobacco smoking is one of the most common risk factors for pancreatic cancer, as smokers have a two-fold increased risk of developing the disease compared with nonsmokers (Lowenfels and Maisonneuve, 2006). Due to the short survival period and high mortality for pancreatic cancer, patients with the disease are less likely to suffer from comorbidities than patients with other types of cancer.
GlobalData forecasts that the US and Germany will have the highest number of incident cases of pancreatic cancer in 2022. GlobalData epidemiologists also expect that the number of prevalent cases of pancreatic cancer in the 6MM covered will increase during the forecast period (2012–2022) to a total of 59,675 cases. The stage at diagnosis for pancreatic cancer is correlated with the availability of screening tests and the ability to identify early symptoms. Due to the inability to identify early indications of the illness, pancreatic cancer cases are most commonly diagnosed in Stage IV. Greater research in prevention and early diagnostic testing can help reduce the incidence of the disease. Through early detection, it may be possible to stop the spread of the cancer to other organs and decrease the overall mortality.
Scope
-The Pancreatic Cancer EpiCast Report provides an overview of the risk factors and global trends of pancreatic cancer in the six major markets (US, France, Germany, Italy, Spain, and UK). It includes a 10-year epidemiology forecast of the incident cases of pancreatic cancer segmented by sex, age (in five-year increments beginning at 15 years and ending at ages 85 years and older), stage at diagnosis, the proportion of incident cases that undergo resection, locally-advanced unresectable cases, metastatic cases, and biomarker mutation type (KRAS and HER2) in these markets, along with the prevalent cases.
Reasons to buy
-Develop business strategies by understanding the trends shaping and driving the global pancreatic cancer market.
-Quantify patient populations in the global pancreatic cancer market to improve product design, pricing, and launch plans.
-Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for pancreatic cancer treatment in each of the markets covered.
-Identify patients based on stage at diagnosis, the proportion of incident cases that undergo resection, locally-advanced unresectable cases, metastatic cases, and biomarker mutation type (KRAS and HER2) in these markets covered.
1 Table of Contents
1 Table of Contents 4
1.1 List of Tables 5
1.2 List of Figures 6
2 Introduction 7
2.1 Catalyst 7
3 Epidemiology 8
3.1 Disease Overview 8
3.2 Risk Factors and Comorbidities 8
3.2.1 The risk of developing pancreatic cancer increases with age 9
3.2.2 Tobacco smokers have a two-fold increased risk of pancreatic cancer 9
3.2.3 Diabetes and obesity increase the risk of developing pancreatic cancer 10
3.2.4 At least 10% of pancreatic cancer cases result from a hereditary predisposition 11
3.3 Global Trends 12
3.3.1 United States 12
3.3.2 France 14
3.3.3 Germany 15
3.3.4 Italy 16
3.3.5 Spain 17
3.3.6 United Kingdom 18
3.4 Forecast Methodology 19
3.4.1 Sources Used 20
3.4.2 Forecast Assumptions and Methods 22
3.4.3 Sources Not Used 24
3.5 Epidemiology Forecast 25
3.5.1 Incident Cases of Pancreatic Cancer 25
3.5.2 Total Five-Year Prevalent Cases of Pancreatic Cancer 34
3.6 Discussion 36
3.6.1 Conclusions on Epidemiological Trends 36
3.6.2 Limitations of the Analysis 37
3.6.3 Strengths of the Analysis 37
4 Appendix 39
4.1 Bibliography 39
4.2 About the Authors 42
4.2.1 Epidemiologists 42
4.2.2 Reviewers 42
4.2.3 Franka des Vignes, PhD, Global Director of Epidemiology and Health Policy 45
4.2.4 Bonnie Bain, PhD, Global Head of Healthcare 45
4.3 About GlobalData 46
4.4 About EpiCast 46
4.5 Disclaimer 46
1.1 List of Tables
Table 1: Risk Factors for Pancreatic Cancer 8
Table 2: 6MM, Sources of Pancreatic Cancer IncidenceData 19
Table 3: 6MM, Incident Cases of Pancreatic Cancer, Ages ?15 Years, Men and Women, Select Years, 2012–2022 25
Table 4: 6MM, Incident Cases of Pancreatic Cancer, by Age, Men and Women, N, 2012 27
Table 5: 6MM, Incident Cases of Pancreatic Cancer, by Sex, Ages ?15 Years, N (Row %), 2012 28
Table 6: 6MM, Five-Year Prevalent Cases of Pancreatic Cancer, Ages ?15 Years, Men and Women, Select Years, 2012–2022 34
1.2 List of Figures
Figure 1: US, Incidence and Mortality Rates of Pancreatic Cancer, All Ages, Men and Women, 2008 12
Figure 2: France, Incidence and Mortality Rates of Pancreatic Cancer, All Ages, Men and Women, 2008 14
Figure 3: Germany, Incidence and Mortality Rates of Pancreatic Cancer, All Ages, Men and Women, 2008 15
Figure 4: Italy, Incidence and Mortality Rates of Pancreatic Cancer, All Ages, Men and Women, 2008 16
Figure 5: Spain, Incidence and Mortality Rates of Pancreatic Cancer, All Ages, Men and Women, 2008 17
Figure 6: UK, Incidence and Mortality Rates of Pancreatic Cancer, All Ages, Men and Women, 2008 18
Figure 7: 6MM, Incident Cases of Pancreatic Cancer, Ages ?15 Years, Men and Women, Select Years, 2012–2022 26
Figure 8: 6MM, Incident Cases of Pancreatic Cancer, by Age, Men and Women, N, 2012 27
Figure 9: 6MM, Incident Cases of Pancreatic Cancer by Sex, Ages ?15 Years, 2012 29
Figure 10: 6MM, Age-Standardized Pancreatic Cancer Incidence, 2012 30
Figure 11: 6MM, Incident Cases of Pancreatic Cancer by Stage at Diagnosis, Ages ?15 Years, Men and Women, 2012 31
Figure 12: 6MM, Total Incident Resected, Locally-Advanced Unresected, and Metastatic Pancreatic Cancer Cases, Ages ?15 Years, Men and Women, 2012 32
Figure 13: 6MM, Total Incident Biomarker Cases of Pancreatic Cancer, Ages ?15 Years, Men and Women, 2012 33
Figure 14: 6MM, Total Five-Year Prevalent Cases of Pancreatic Cancer, Ages ?15 Years, Men and Women, Select Years, 2012–2022 35
Read the full report:
EpiCast Report: Pancreatic Cancer - Epidemiology Forecast to 2022
For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: [email protected]
Tel: +44 208 816 85 48
Website: http://www.reportbuyer.com/
Sarah Smith, Research Advisor at Reportbuyer.com, +44 208 816 85 48, [email protected]
Share this article